German China India

France: Biotechnology

Sanofi to Sell European Generic-Drug Unit to Advent

| Editor: Alexander Stark

Sanofi plans to sell its European generic-drug unit to buyout firm Advent International.
Sanofi plans to sell its European generic-drug unit to buyout firm Advent International. (Source: Bloomberg Finance LP)

Sanofi plans to sell its European generic-drug unit to buyout firm Advent International for $ 2.4 billion as part of a broader move by Chief Executive Officer Olivier Brandicourt to focus resources on biotechnology and new medicines.

Paris/France (Bloomberg) — Advent has made a binding and fully financed offer, and the companies are in exclusive negotiations, Paris-based Sanofi said in a statement Tuesday. The deal should close by the end of the year, it said.

Brandicourt has undertaken a series of transactions to shift Sanofi towards businesses with more potential for growth. The company has announced about $ 16 billion of deals this year, agreeing to buy Bioverativ to expand in hemophilia treatments and Ablynx to gain an experimental medicine for another rare bleeding disorder.

Advent Close to Acquiring Sanofi's European Generics Division

France: Pharmaceutical Industry

Advent Close to Acquiring Sanofi's European Generics Division

16/04/2018 - Advent International is apparently close to acquiring Sanofi’s European generics division in a deal valued at about $ 2.5 billion including debt. read...

The French company isn’t the only drugmaker revamping its product offerings and pipeline to adjust to industry changes. Novartis also on Tuesday began a $ 8.7 billion cash offer for Avexis to gain at least one promising experimental drug for a rare and often fatal disease, using some of the $ 13 billion from selling its stake in a consumer-health joint venture. Glaxo Smith Kline has also been reviewing its portfolio, and is offloading its rare-disease division to a biotechnology company as treatment sales have flagged.

Comments are being loaded ....

Leave a comment

The comment is checked by an editor and will be released soon.

  1. Avatar
    Avatar
    Edited by at
    Edited by at
    1. Avatar
      Avatar
      Edited by at
      Edited by at

Comments are being loaded ....

Report comment

Kommentar Freigeben

Der untenstehende Text wird an den Kommentator gesendet, falls dieser eine Email-hinterlegt hat.

Freigabe entfernen

Der untenstehende Text wird an den Kommentator gesendet, falls dieser eine Email-hinterlegt hat.

copyright

This article is protected by copyright. You want to use it for your own purpose? Contact us via: support.vogel.de/ (ID: 45254272 / Pharma & Food)